TrialThe Journal of infectious diseases2013

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Lindsey R Baden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.